The United States accounts for the largest share of global peptide research output, driven by the scale of National Institutes of Health funding and a dense concentration of academic and commercial research capacity. It also has the most contested regulatory environment for peptides, because the line between a research chemical, a compounded preparation and an approved drug has become an active area of enforcement.
All products supplied by North Specs Labs are Research Use Only and are not for human or veterinary use. This article describes the regulatory landscape; it is not legal advice.
Funding
The National Institutes of Health is the dominant funder. Peptide research is distributed across institutes according to application: the National Institute of Diabetes and Digestive and Kidney Diseases for metabolic work, the National Cancer Institute for oncology-directed peptides, the National Institute of General Medical Sciences for underlying chemistry and structural biology, and the National Institute on Aging for cellular ageing and mitochondrial peptide research.
The National Science Foundation supports the chemistry and materials side. The Department of Defense funds work with trauma, wound healing and countermeasure applications, which has historically supported a portion of tissue-repair peptide research.
The Small Business Innovation Research programme is significant in this field specifically, because peptide therapeutics have a lower barrier to early development than biologics and are therefore accessible to small companies.
Concentration
Peptide research clusters where broader life-science capacity clusters: the Boston and Cambridge corridor, the San Francisco Bay Area, San Diego, the Research Triangle in North Carolina, and around major midwestern research universities.
Certain institutions carry particular association with the field. Work on incretin biology and gut hormone signalling has notable centres in the midwest and southeast. Structural biology of peptide-receptor complexes is strong at institutions with cryo-electron microscopy capacity, which has transformed the field by making receptor complexes tractable. Mitochondrial-derived peptide research, including the discovery of humanin and MOTS-c, has been concentrated at a small number of west-coast institutions.
Regulatory framework
This is where the American picture becomes complicated, and where researchers most often encounter confusion.
Research use. A peptide supplied and used strictly as a laboratory reagent, not represented for therapeutic use, is a research chemical. It is not an FDA-approved product and does not need to be. The Research Use Only designation marks this status.
Approved drugs. A peptide developed as a therapeutic goes through the Investigational New Drug and New Drug Application pathway. Several peptides have completed this, including incretin analogues and a number of hormone analogues, and are approved for specific indications.
The compounding question. Sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act govern compounding pharmacies and outsourcing facilities. Compounding permits preparation of medications for specific patient needs, but the substances used must meet defined criteria.
In recent years the FDA has evaluated a number of peptides for inclusion on the lists governing what may be compounded, and has placed several into a category identified as raising significant safety risks, which restricts their compounding. Several peptides commonly discussed in non-clinical contexts, including BPC-157, fall within this regulatory attention. The agency has also issued warning letters concerning marketing of peptides for human use without approval.
The practical consequence for a researcher is that the regulatory status of a peptide as a research chemical is distinct from its status as something that may lawfully be compounded or administered. A material may be entirely legitimate to purchase and use as a laboratory reagent while being clearly outside what may lawfully be prepared for human administration.
Controlled substances. Most research peptides are not scheduled under the Controlled Substances Act. Some related compounds are, and status should be verified per compound.
Anti-doping. The World Anti-Doping Agency prohibits a range of peptides, including growth hormone secretagogues, GHRH analogues and several tissue-repair peptides. The US Anti-Doping Agency enforces this for athletes in scope. This is independent of FDA status and catches compounds that are otherwise unremarkable as research chemicals.
Institutional oversight. Human subjects research requires Institutional Review Board approval. Animal work requires Institutional Animal Care and Use Committee approval. Laboratory safety falls under OSHA's Laboratory Standard, which requires a Chemical Hygiene Plan.
What this means practically
Several points follow for a laboratory sourcing research peptides in the United States.
The RUO designation is substantive, not cosmetic. It marks a genuine regulatory category, and it depends on the material actually being used for research. A supplier that labels material RUO while marketing it with therapeutic claims is not in that category, and neither is a purchaser who buys under that designation for other purposes.
Documentation matters for institutional procurement. Batch-specific certificates of analysis are increasingly expected by institutional purchasing and safety offices, and are the basis on which a purity specification can be relied upon at all.
Import is a real consideration. Research materials entering the United States are subject to customs inspection, and shipments to institutional addresses with clear documentation move more predictably than those without.
Regulatory status changes. The compounding lists and enforcement priorities have moved considerably in recent years. A compound's status should be checked at the time of acquisition rather than assumed from earlier practice.
Research directions
American output is concentrated in a few areas. Metabolic peptide research, driven by the commercial and clinical success of incretin agonists, is the largest. Peptide-drug conjugates for targeted oncology delivery are an active field. Antimicrobial peptides attract sustained interest as resistance concerns grow. Computational and machine-learning approaches to de novo peptide design, particularly for targets with no natural ligand, have moved quickly. And cryo-electron microscopy of peptide-receptor complexes has made structure-based design feasible for targets that were previously inaccessible.
North Specs Labs supplies research-grade peptides to qualified researchers, laboratories and research institutions. All products are Research Use Only and are not for human consumption or veterinary use.
North Specs separates research education from product claims. Readers should review primary literature and institutional requirements before designing laboratory work.